1,581
Views
3
CrossRef citations to date
0
Altmetric
ORIGINAL ARTICLES: CANCER EPIDEMIOLOGY

Mortality from cardiovascular disease in women with breast cancer – a nationwide registry study

ORCID Icon, , , ORCID Icon, , & show all
Pages 1257-1263 | Received 28 Jan 2021, Accepted 19 Jul 2021, Published online: 02 Aug 2021

References

  • The Global Cancer Observatory. World fact sheet; 2021; [Internet]. Available from: https://gco.iarc.fr/today/data/factsheets/populations/900-world-fact-sheets.pdf
  • NORDCAN. NORDCAN projektet – Kraeftstatistik for de nordiske lande; 2021; [Internet]. Available from: http://www-dep.iarc.fr/NORDCAN/DK/frame.asp
  • Gernaat SAM, Ho PJ, Rijnberg N, et al. Risk of death from cardiovascular disease following breast cancer: a systematic review. Breast Cancer Res Treat. 2017;164(3):537–555.
  • Mehta LS, Watson KE, Barac A, et al. Cardiovascular disease and breast cancer: where these entities intersect: a scientific statement from the American Heart Association. Circulation. 2018;137(8):e30–e66.
  • Schmoldt A, Benthe HF, Haberland G. Metabolic syndrome and the risk of breast cancer and subtypes by race, menopause and BMI. Biochem Pharmacol. 1975;24(17):1639–1641.
  • Cronin-Fenton DP, Nørgaard M, Jacobsen J, et al. Comorbidity and survival of Danish breast cancer patients from 1995 to 2005. Br J Cancer. 2007;96(9):1462–1468.
  • Ewertz M, Land LH, Dalton SO, et al. Influence of specific comorbidities on survival after early-stage breast cancer. Acta Oncol. 2018;57(1):129–134.
  • Land LH, Dalton SO, Jensen MB, et al. Impact of comorbidity on mortality: a cohort study of 62,591 Danish women diagnosed with early breast cancer, 1990–2008. Breast Cancer Res Treat. 2012;131(3):1013–1020.
  • Land LH, Dalton SO, Jensen MB, et al. Influence of comorbidity on the effect of adjuvant treatment and age in patients with early-stage breast cancer. Br J Cancer. 2012;107(11):1901–1907.
  • Søgaard M, Thomsen RW, Bossen KS, et al. The impact of comorbidity on cancer survival: a review. Clin Epidemiol. 2013;5(Suppl. 1):3–29.
  • Land LH, Dalton SO, Jorgensen TL, et al. Comorbidity and survival after early breast cancer. A review. Crit Rev Oncol Hematol. 2012;81(2):196–205.
  • Bradshaw PT, Stevens J, Khankari N, et al. Cardiovascular disease mortality among breast cancer survivors. Epidemiology. 2016;27(1):6–13.
  • Riihimaki M, Thomsen H, Brandt A, et al. Death causes in breast cancer patients. Ann Oncol. 2012;23(3):604–610.
  • Gjerstorff ML. The Danish Cancer Registry. Scand J Public Health. 2011;39(7 Suppl.):42–45.
  • Helweg-Larsen K. The Danish register of causes of death. Scand J Public Health. 2011;39(7 Suppl.):26–29.
  • World Health Organization (WHO). International statistical classification of diseases and related health problems, 10th revision. Vol. 2, instruction manual. 2010 ed. Geneva, Switzerland: WHO; 2011.
  • Lynge E, Sandegaard JL, Rebolj M. The Danish National Patient Register. Scand J Public Health. 2011;39(7 Suppl.):30–33.
  • Pedersen CB. The Danish Civil Registration System. Scand J Public Health. 2011;39(7 Suppl.):22–25.
  • Jensen VM, Rasmussen AW. Danish education registers. Scand J Public Health. 2011;39(7 Suppl.):91–94.
  • Ramin C, Schaeffer ML, Zheng Z, et al. All-cause and cardiovascular disease mortality among breast cancer survivors in CLUE II, a long-standing community-based cohort. J Natl Cancer Inst. 2021;113(2):137–145.
  • Buddeke J, Gernaat SAM, Bots ML, et al. Trends in the risk of cardiovascular disease in women with breast cancer in a Dutch Nationwide Cohort Study. BMJ Open. 2019;9(5):e022664.
  • Austin PC, Lee DS, Fine JP. Introduction to the analysis of survival data in the presence of competing risks. Clin Epidemiol. 2016;133(6):601–609.
  • Pintilie M. Analysing and interpreting competing risk data. Stat Med. 2007;26(6):1360–1367.
  • Pintilie M. Introduction; competing risks – definitions; descriptive methods for competing risks data. Competing Risks. 2006.
  • Gooley TA, Leisenring W, Crowley J, et al. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med. 1999;18(6):695–706.
  • Marubini E, Valsecchi MG. Analysing survival  data from clinical trials and observational studies. Chichester: Wiley; 1995.
  • Coviello V, Boggess M. Cumulative incidence estimation in the presence of competing risks. Stata J. 2004;4(2):103–112.
  • Pepe MS, Mori M. Kaplan–Meier, marginal or conditional probability curves in summarizing competing risks failure time data? Stat Med. 1993;12(8):737–751.
  • Coviello E. STPEPEMORI: Stata module to test the equality of cumulative incidences across two groups in the presence of competing risks, statistical software components, S456899. Boston College Department of Economics (revised 2010); 2008.
  • Jakobsen M, Jensen M, Kolodziejczyk C. Komorbiditet ved brystkraeft – Et registerstudie om konkurrerende sygdom før og efter brystkraeftdiagnose med fokus på hjerte-kar-sygdom. Copenhagen: VIVE; 2020.
  • Hamer J, Warner E. Lifestyle modifications for patients with breast cancer to improve prognosis and optimize overall health. CMAJ. 2017;189(7):E268–E274.
  • Skyrud KD, Bray F, Møller B. A comparison of relative and cause-specific survival by cancer site, age and time since diagnosis. Int J Cancer. 2014;135(1):196–203.
  • Nguyen-Nielsen M, Moller H, Tjonneland A, et al. Causes of death in men with prostate cancer: results from the Danish Prostate Cancer Registry (DAPROCAdata). Cancer Epidemiol. 2019;59:249–257.